Send us Feedback

Eli Lilly and Company (LLY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

LLY » Topics » Pharmaceutical Marketing Collaborations

This excerpt taken from the LLY 10-K filed Feb 22, 2010.
Pharmaceutical Marketing Collaborations
We market certain of our significant products in collaboration with other pharmaceutical companies:
 
  •  Under an arrangement that ended in 2009, Cymbalta was co-promoted in the United States by Quintiles Transnational Corp. Cymbalta is co-marketed in Japan by Shionogi & Co. Ltd. and is co-promoted or co-marketed in most other major countries outside the U.S. by Boehringer Ingelheim GmbH.
 
  •  Evista is marketed in major European markets by Daiichi Sankyo Europe GmbH, a subsidiary of Daiichi Sankyo Co., Ltd. of Japan.
 
  •  We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the United States and Puerto Rico, and we have exclusive marketing rights in other territories.
 
  •  Erbitux is marketed in North America by Bristol-Myers Squibb. We co-promote Erbitux in North America. Outside North America, Erbitux is commercialized by Merck KGaA. We receive royalties from Bristol-Myers Squibb and Merck KGaA.
 
  •  Effient is co-promoted with us by Daiichi Sankyo in the United States, major European markets, Brazil, Mexico, China, and several other Asian countries. Daiichi Sanko retains sole marketing rights in Japan, and we retain sole marketing rights in Canada, Australia, Russia, and certain other countries.
 
These excerpts taken from the LLY 10-K filed Feb 27, 2009.
Pharmaceutical Marketing Collaborations
 
We market certain of our significant products in collaboration with other pharmaceutical companies:
 
  •   Cymbalta is co-promoted in the United States by Quintiles Transnational Corp. and is co-promoted or co-marketed outside the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •   Evista is marketed in major European markets by Daiichi Sankyo Europe GmbH, a subsidiary of Daiichi Sankyo Co., Ltd. of Japan.
 
  •   We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the United States and Puerto Rico, and we have exclusive marketing rights in other territories.
 
  •   Erbitux is marketed in North America by Bristol-Myers Squibb. We co-promote Erbitux in North America. Outside North America, Erbitux is commercialized by Merck KGaA. We receive royalties from Bristol-Myers Squibb and Merck KGaA.
 
  •   Efient will be co-promoted with us in major European markets by Daiichi Sankyo Europe GmbH. Assuming regulatory approvals, Daiichi Sankyo will also co-promote the product with us in the United States, Brazil, Mexico, China and several other Asian countries. Daiichi Sanko retains sole marketing rights in Japan, and we retain sole marketing rights in Canada, Australia, Russia and certain other countries.  


-3-

 

 
Pharmaceutical
Marketing Collaborations


 



We market certain of our significant products in collaboration
with other pharmaceutical companies:


 
























































  •  
Cymbalta is co-promoted in the United States by Quintiles
Transnational Corp. and is co-promoted or co-marketed outside
the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •  
Evista is marketed in major European markets by Daiichi Sankyo
Europe GmbH, a subsidiary of Daiichi Sankyo Co., Ltd. of Japan.
 
  •  
We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the
United States and Puerto Rico, and we have exclusive marketing
rights in other territories.
 
  •  
Erbitux is marketed in North America by Bristol-Myers Squibb. We
co-promote Erbitux in North America. Outside North America,
Erbitux is commercialized by Merck KGaA. We receive royalties
from Bristol-Myers Squibb and Merck KGaA.
 
  •  
Efient will be
co-promoted
with us in major European markets by Daiichi Sankyo Europe GmbH.
Assuming regulatory approvals, Daiichi Sankyo will also
co-promote
the product with us in the United States, Brazil, Mexico, China
and several other Asian countries. Daiichi Sanko retains sole
marketing rights in Japan, and we retain sole marketing rights
in Canada, Australia, Russia and certain other
countries.  





-3-




 





 




These excerpts taken from the LLY 10-K filed Oct 21, 2008.
Pharmaceutical Marketing Collaborations
 
Several of our significant products are marketed in collaboration with other pharmaceutical companies:
 
  •   Cymbalta is co-promoted in the United States by Quintiles Transnational Corp. and is co-promoted or co-marketed outside the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •   Through January 2007, Cialis was sold in North America and most of Europe by a joint venture between Lilly and ICOS Corporation, and was sold by us alone in other territories. On January 29, 2007, we acquired all the outstanding common stock of ICOS. Following the acquisition, Cialis is sold by Lilly in all territories.
 
  •   We co-promoted Actos with a unit of Takeda Chemical Industries Ltd. in the United States until our U.S. marketing rights expired in September 2006; however, we are receiving residual royalties on U.S. Actos sales at declining annual rates through September 2009. We continue to have exclusive and semi-exclusive marketing rights to Actos in other countries.
 
  •   We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the United States and Puerto Rico, and we have exclusive marketing rights in other territories.
 
We have also entered into licensing arrangements under which we have granted exclusive marketing rights to other companies in specified countries for certain older products manufactured by us, such as Ceclor and Vancocin.
 
Pharmaceutical
Marketing Collaborations


 



Several of our significant products are marketed in
collaboration with other pharmaceutical companies:


 














































  •  
Cymbalta is co-promoted in the United States by Quintiles
Transnational Corp. and is co-promoted or co-marketed outside
the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •  
Through January 2007, Cialis was sold in North America and most
of Europe by a joint venture between Lilly and
ICOS Corporation, and was sold by us alone in other
territories. On January 29, 2007, we acquired all the
outstanding common stock of ICOS. Following the acquisition,
Cialis is sold by Lilly in all territories.
 
  •  
We co-promoted Actos with a unit of Takeda Chemical Industries
Ltd. in the United States until our U.S. marketing rights
expired in September 2006; however, we are receiving residual
royalties on U.S. Actos sales at declining annual rates
through September 2009. We continue to have exclusive and
semi-exclusive marketing rights to Actos in other countries.
 
  •  
We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the
United States and Puerto Rico, and we have exclusive marketing
rights in other territories.


 



We have also entered into licensing arrangements under which we
have granted exclusive marketing rights to other companies in
specified countries for certain older products manufactured by
us, such as Ceclor and Vancocin.


 




These excerpts taken from the LLY 10-K filed Feb 29, 2008.
Pharmaceutical Marketing Collaborations
 
Several of our significant products are marketed in collaboration with other pharmaceutical companies:
 
  •   Cymbalta is co-promoted in the United States by Quintiles Transnational Corp. and is co-promoted or co-marketed outside the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •   Through January 2007, Cialis was sold in North America and most of Europe by a joint venture between Lilly and ICOS Corporation, and was sold by us alone in other territories. On January 29, 2007, we acquired all the outstanding common stock of ICOS. Following the acquisition, Cialis is sold by Lilly in all territories.
 
  •   We co-promoted Actos with a unit of Takeda Chemical Industries Ltd. in the United States until our U.S. marketing rights expired in September 2006; however, we are receiving residual royalties on U.S. Actos sales at declining annual rates through September 2009. We continue to have exclusive and semi-exclusive marketing rights to Actos in other countries.
 
  •   We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the United States and Puerto Rico, and we have exclusive marketing rights in other territories.
 
We have also entered into licensing arrangements under which we have granted exclusive marketing rights to other companies in specified countries for certain older products manufactured by us, such as Ceclor and Vancocin.
 
Pharmaceutical
Marketing Collaborations


 



Several of our significant products are marketed in
collaboration with other pharmaceutical companies:


 














































  •  
Cymbalta is co-promoted in the United States by Quintiles
Transnational Corp. and is co-promoted or co-marketed outside
the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •  
Through January 2007, Cialis was sold in North America and most
of Europe by a joint venture between Lilly and
ICOS Corporation, and was sold by us alone in other
territories. On January 29, 2007, we acquired all the
outstanding common stock of ICOS. Following the acquisition,
Cialis is sold by Lilly in all territories.
 
  •  
We co-promoted Actos with a unit of Takeda Chemical Industries
Ltd. in the United States until our U.S. marketing rights
expired in September 2006; however, we are receiving residual
royalties on U.S. Actos sales at declining annual rates
through September 2009. We continue to have exclusive and
semi-exclusive marketing rights to Actos in other countries.
 
  •  
We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the
United States and Puerto Rico, and we have exclusive marketing
rights in other territories.


 



We have also entered into licensing arrangements under which we
have granted exclusive marketing rights to other companies in
specified countries for certain older products manufactured by
us, such as Ceclor and Vancocin.


 




This excerpt taken from the LLY 10-K filed Feb 28, 2007.
Pharmaceutical Marketing Collaborations
 
Several of our significant products are marketed in collaboration with other pharmaceutical companies:
 
  •   Cymbalta is co-promoted in the United States by Quintiles Transnational Corp. and is co-promoted or co-marketed outside the U.S. (except Japan) by Boehringer Ingelheim GmbH.
 
  •   Through January 2007, Cialis was sold in North America and most of Europe by a joint venture between Lilly and ICOS Corporation, and was sold by us alone in other territories. On January 29, 2007, we acquired all the outstanding common stock of ICOS. Following the acquisition, Cialis is sold by Lilly in all territories.
 
  •   We co-promoted Actos with a unit of Takeda Chemical Industries Ltd. in the United States until our U.S. marketing rights expired in September 2006; however, we will receive residual royalties on U.S. Actos sales for three years thereafter. We continue to have exclusive and semi-exclusive marketing rights to Actos in other countries.
 
  •   We co-promote Byetta with Amylin Pharmaceuticals, Inc. in the United States and Puerto Rico, and we have exclusive marketing rights in other territories.
 
We have also entered into licensing arrangements under which we have granted exclusive marketing rights to other companies in specified countries for certain older products manufactured by us, such as Ceclor and Vancocin.
 

EXCERPTS ON THIS PAGE:

10-K
Feb 22, 2010
10-K (2 sections)
Feb 27, 2009
10-K (2 sections)
Oct 21, 2008
10-K (2 sections)
Feb 29, 2008
10-K
Feb 28, 2007

RELATED TOPICS for LLY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki